Discover 878 paid clinical trials in Kentucky. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Kentucky presents diverse clinical research opportunities for healthy volunteers looking to get involved in paid studies, and those with specific health conditions alike. Major research centers in Louisville, Lexington, and Bowling Green are actively seeking participants, offering access to new treatments and advanced medical care.
Filter
1
Filter results
Results: 878
FeaturedActive & Responsive
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Boston MA, Providence RI, North Massapequa NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819878
Phase 3, Recruiting
Featured
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
for
Crohn's Disease
Location: New Bedford MA, New Haven CT, Quebec, Danbury CT,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT06548542
Phase 2, Recruiting
Featured
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Providence RI, North Worcester MA, Lebanon NH,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819891
Phase 3, Recruiting
Featured
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
for
Crohn's Disease, Ulcerative Colitis
Location: New Bedford MA, Providence RI, Quebec, New York NY,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT07697456
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Boston MA, Mullica Hill NJ, Bethlehem PA, Fairfax VA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07365241
Phase 3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: Scarborough ME, Worcester MA, New York NY, Camden NJ,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07059845
Phase 2, Recruiting
Featured
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
for
Obesity or Overweight
Location: Boston MA, Needham MA, New Haven CT, Quebec,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351045
Phase 3, Recruiting
Featured
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Boston MA, New Haven CT, Fairfax VA, Ocala FL, Tampa FL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07155174
Phase 2, Recruiting
Featured
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
for
Obesity, Overweight
Location: Morehead City NC, Newport News VA, New Bern NC,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT07752979
Phase 2, Recruiting
Featured
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for
Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: Providence RI, New Haven CT, Lebanon NH, Bay Shore NY,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06890338
Phase 2, Recruiting
Featured
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
for
Von Willebrand Disease, Type 3
Location: Montreal, Richmond VA, Toronto, Gainesville FL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0+
Code: NCT06998524
Phase 3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Moncton, Shirley NY, The Bronx NY, New York NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06790693
Phase 3, Recruiting
Featured
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
for
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Location: Boston MA, Albany NY, Virginia Beach VA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06806033
Phase 2, Recruiting
Featured
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
for
Migraine
Location: Nashua NH, Stamford CT, Morristown NJ, Philadelphia PA,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05125302
Phase 3, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)